Replies to post #370375 on Anavex Life Sciences Corp (AVXL)

[1950jtom]

Good point, and I did think about pricing. A lock-down Alzheimer’s facility (in the US) will cost between $50k and $100k per year. If a resident could be moved into the assisted living area, instead, it would cut that cost substantially.

I suspect there are a lot of pricing scenarios going on at Anavex these days. If they wanted to suck all the air out of other AD and PDD research and investment, they could do so by pricing the drug within reach of a few.

At any rate, I suspect we could see some off-labeling use, and with no NDAs to restrict public disclosure of results, that could prove very interesting, especially to investors.